Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Confidential contracting

Bayer symbol

Bayer gains FDA priority review for prostate cancer drug

Could compete against J&J’s Erleada and Pfizer/Astellas’ Xtandi

- PMLiVE

OPEN Health Medical Communications announces Group MD promotions and welcomes new Creative Director

OPEN Health Medical Communications has announced the promotion of two members of its senior leadership team. Jen van Zwieten and Margot Hannah become Group Managing Directors, with responsibility to oversee...

OPEN Health

Roche Basel Switzerland

Roche to present new data on Spinraza rival

As Novartis stumbles, Roche pushing first oral SMA treatment

- PMLiVE

UK to add addiction warnings to opioids as use soars

Codeine-related deaths doubled in a decade

- PMLiVE

Lynparza could soon add first line ovarian use in Europe

Also first PARP inhibitor launched in China

It’s Complicated

Commercial executives should be more like their scientist colleagues

- PMLiVE

CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

Opioid dependence therapy and Pfizer's PARP inhibitor also recommended

AstraZeneca AZ

Oncology drives AstraZeneca, Genzyme boosts Sanofi

Specialist drugs are growth engines in Q1

- PMLiVE

Orphan drugs market to soar to $224bn by 2024

Cell and gene therapies to fuel growth

15 Personalized Medicine: It’s Time To Get Creative

Havas Lynx

14 Interpreting the Future of Healthcare

Havas Lynx

- PMLiVE

Lilly to withdraw Lartruvo, a first for accelerated approval failures

Existing patients can use access programme

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links